---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-26-000146"
form_type: "8-K"
ticker: "TLRY"
cik: "0001731348"
company_name: "Tilray Brands, Inc."
filed_at: "2026-01-08T23:59:59+00:00"
generated_at: "2026-05-16T11:13:54.138220+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "medium"
source: SEC EDGAR
---

# Tilray Brands Q2 FY2026 revenue record $218M; net cash $30M; reaffirms EBITDA guidance

## Summary
- Net revenue $218M, a record quarterly; international medical cannabis revenue increased 36% YoY.
- Ended quarter with $292M cash and marketable securities; net cash position of approximately $30M.
- Canadian adult-use cannabis revenue grew 6% YoY; Tilray Pharma achieved record quarterly revenue.
- Reaffirmed full-year adjusted EBITDA guidance; Chairman cites disciplined execution and long-term value.
- U.S. federal cannabis rescheduling expected to unlock new market opportunity for Tilray Medical expansion.

## SEC filing metadata
- accession: 0001171843-26-000146
- form_type: 8-K
- ticker: TLRY
- cik: 0001731348
- company_name: Tilray Brands, Inc.
- filed_at: 2026-01-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: medium
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1731348/000117184326000146/0001171843-26-000146-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1731348/000117184326000146/f8k_010826.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-26-000146
- JSON: https://secwatch.observer/filing/0001171843-26-000146.json
- Plain text: https://secwatch.observer/filing/0001171843-26-000146.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.